Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 15/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299488 | 0.96 | PAK1 (0.54) | PAK1ALKPAK4AAK1TNIK | |
| SCHEMBL298907 | 0.86 | BRAF (0.54) | PAK1ALK | |
| SCHEMBL297940 | 0.86 | PAK1 (0.53) | PAK1ALKPAK4 | |
| SCHEMBL3710491 | 0.85 | PAK1 (0.57) | PAK1ALKPAK4 | |
| SCHEMBL297385 | 0.84 | CYP3A4 (0.51) | PAK1ALK | |
| SCHEMBL298470 | 0.84 | PIK3CA (0.50) | PAK1ALK | |
| SCHEMBL298410 | 0.84 | BRAF (0.49) | PAK1ALK | |
| SCHEMBL298148 | 0.84 | EGFR (0.57) | PAK1ALKPAK4 | |
| SCHEMBL298351 | 0.84 | PIK3CA (0.49) | PAK1ALKAAK1TNIK | |
| SCHEMBL3704923 | 0.83 | PAK1 (0.56) | PAK1ALKPAK4AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | PAK1 290/4885ALK 679/4885PAK4 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.